Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

(Nasdaq VIRI at, a biotechnology organization zeroed in on propelling novel antiviral treatments to treat infections related with a viral set off an irregular safe reaction, declared today that Greg Duncan, Chairman, and Chief Executive Officer, and R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer, will introduce an organization outline at the H.C.

The introduction will be accessible for on-request access starting Monday, January 11, 2021, at 6:00 AM ET, on Virios Therapeutics’ site under the Investors area: Events and Presentations.

About Virios Therapeutics

Virios Therapeutics is an improvement stage biotechnology organization zeroed in on propelling novel antiviral treatments to treat sicknesses related with a viral set off a strange insusceptible reaction, for example, fibromyalgia (“FM”). Overactive invulnerable reaction identified with actuation of tissue occupant Herpes Simplex Virus-1 (“HSV-1”) has been hypothesized to be a potential main driver of ongoing sicknesses, for example, FM, fractious gut infection (“IBS”), persistent weariness disorder, and utilitarian substantial condition, which are all described by a coming and going appearance of illness. While not comprehended, there is a general understanding in the clinical local area that the actuation of HSV-1 is set off by some type of natural or potentially wellbeing stressor. Our lead advancement applicant (“IMC-1”), is a novel, restrictive, fixed portion mix of famciclovir and celecoxib. IMC-1 addresses a novel blend antiviral treatment intended to synergistically stifle HSV-1 initiation and replication, with the ultimate objective of lessening viral interceded infection trouble.

Forward-Looking Statements

Proclamations in this public statement contain “forward-looking articulations” that are dependent upon generous dangers and vulnerabilities. All assertions, other than articulations of chronicled certainty, contained in this public statement are forward-looking explanations. Forward-glancing proclamations contained in this public statement might be distinguished by the utilization of words, for example, “foresee,” “accept,” “think about,” “could,” “gauge,” “expect,” “mean,” “look for,” “may,” “might,” “plan,” “potential,” “anticipate,” “project,” “target,” “point,” “ought to,” “will” “would,” or the negative of these words or other comparable articulations, albeit not all forward-looking explanations contain these words.

Forward-looking proclamations depend on Virios Therapeutics’ present assumptions and are dependent upon characteristic vulnerabilities, dangers, and suspicions that are hard to foresee. Further, sure forward-looking proclamations depend on suspicions as to future occasions that may not end up being exact. These and different dangers and vulnerabilities are depicted all the more completely in the segment named “Danger Factors” in the last plan identified with the public contribution documented with the Securities and Exchange Commission. Forward-glancing articulations contained in this declaration are made as of this date, and Nasdaq VIRI. attempts no obligation to refresh such data besides as needed under pertinent law. You can check other stocks like nasdaq tsla at before investing.

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *